MNX.V - Manitex Capital Inc.
| Previous Close | 0.1600 |
| Open | 0.1400 |
| Bid | 0.1350 x 0 |
| Ask | 0.2500 x 0 |
| Day's Range | 0.1350 - 0.1400 |
| 52 Week Range | 0.1350 - 0.4200 |
| Volume | 2,000 |
| Avg. Volume | 1,914 |
| Market Cap | 1.696M |
| Beta (3Y Monthly) | 2.81 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2600 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.•last month
Do Insiders Own Lots Of Shares In Manitex Capital Inc. (CVE:MNX)?
If you want to know who really controls Manitex Capital Inc. (CVE:MNX), then you'll have to look at the makeup of its...
- CNW Group•3 months ago
Manitex Capital Inc. announces results of AGM
KIRKLAND, QC, April 5, 2019 /CNW Telbec/ - Manitex Capital Inc. ("Manitex" or the "Company") is pleased to announce the voting results from its Annual General and Special Meeting of shareholders (the "Meeting") held today in Kirkland, Quebec. The total number of shares represented by shareholders present in person and by proxy at the Meeting was 8,017,627 representing 63.83% of the Company's issued and outstanding shares.
- Simply Wall St.•4 months ago
Introducing Manitex Capital (CVE:MNX), The Stock That Zoomed 105% In The Last Five Years
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, you can make far more than 100%Read More...
- CNW Group•5 months ago
Manitex Capital Inc.'s affiliate, Valeo Pharma Inc., announces approval of Onstryv® (safinamide) for Canada
KIRKLAND, QC, Jan. 15, 2019 /CNW Telbec/ - Manitex Capital Inc. (TSXV:MNX.V - News) announces that its affiliate, Valeo Pharma Inc., has received approval from Health Canada for a new Parkinson's Disease product ONSTRY® (safinamide) in Canada. Valeo Pharma plans to launch ONSTRYV® in Canada in the first half of 2019.
- CNW Group•5 months ago
Manitex Capital Inc. declares a dividend-in-kind of shares of Valeo Pharma Inc.
KIRKLAND, QC, Jan. 11, 2019 /CNW Telbec/ - Manitex Capital Inc. ("Manitex") is pleased to announce that its board of directors has declared a special dividend-in-kind (the "Dividend") of 1,256,127 common shares of Valeo Pharma Inc., ("Valeo") held by Manitex. The Dividend has a deemed price of $0.40 per Valeo Share and is payable on, or about, February 1, 2019 to holders of record of common shares of Manitex ("Manitex Shares") at the close of business on January 22, 2019 (the "Record Date").
- CNW Group•7 months ago
Manitex Capital Inc. announces director resignation
KIRKLAND, QC , Nov. 21, 2018 /CNW Telbec/ - Manitex Capital Inc. (" Manitex " or the " Corporation ") announces that Mr. David Ben-David has resigned from its Board of Directors effective ...
- Simply Wall St.•9 months ago
Is Manitex Capital Inc’s (CVE:MNX) Balance Sheet Strong Enough To Weather A Storm?
Investors are always looking for growth in small-cap stocks like Manitex Capital Inc (CVE:MNX), with a market cap of CA$4m. However, an important fact which most ignore is: how financially Read More...
- CNW Group•9 months ago
Manitex Capital Inc. Announces That Its Affiliate Valeo Pharma Inc. Has Filed a Non-Offering Preliminary Prospectus
KIRKLAND, QC, Oct. 1, 2018 /CNW Telbec/ - Manitex Capital Inc. ("Manitex") (TSXV:MNX.V - News) is pleased to announce that its affiliate, Valeo Pharma Inc. ("Valeo Pharma"), has filed a non-offering preliminary prospectus with the securities regulatory authorities of all provinces and territories in Canada. The non-offering prospectus is being filed for the purpose of allowing Valeo Pharma to become a reporting issuer in all jurisdictions of Canada and to become eligible for listing pursuant to the policies of the TSX Venture Exchange ("TSXV"). Listing will be subject to Valeo Pharma fulfilling all of the listing requirements of the TSXV.
